- Home
- ADAG vs MDXH Comparison
ADAG vs MDXH Comparison
Compare ADAG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- MDXH
- Stock Information
- Founded
- ADAG 2011
- MDXH 2003
- Country
- ADAG China
- MDXH Belgium
- Employees
- ADAG N/A
- MDXH N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- ADAG Health Care
- MDXH
- Exchange
- ADAG Nasdaq
- MDXH Nasdaq
- Market Cap
- ADAG 81.9M
- MDXH 93.1M
- IPO Year
- ADAG 2021
- MDXH 2021
- Fundamental
- Price
- ADAG $2.06
- MDXH $1.86
- Analyst Decision
- ADAG Strong Buy
- MDXH Strong Buy
- Analyst Count
- ADAG 1
- MDXH 2
- Target Price
- ADAG $8.00
- MDXH $7.00
- AVG Volume (30 Days)
- ADAG 31.8K
- MDXH 58.0K
- Earning Date
- ADAG 03-09-2025
- MDXH 02-26-2025
- Dividend Yield
- ADAG N/A
- MDXH N/A
- EPS Growth
- ADAG N/A
- MDXH N/A
- EPS
- ADAG N/A
- MDXH N/A
- Revenue
- ADAG $815,746.00
- MDXH $84,708,000.00
- Revenue This Year
- ADAG N/A
- MDXH $28.76
- Revenue Next Year
- ADAG $2.70
- MDXH $19.91
- P/E Ratio
- ADAG N/A
- MDXH N/A
- Revenue Growth
- ADAG N/A
- MDXH 33.01
- 52 Week Low
- ADAG $1.64
- MDXH $1.55
- 52 Week High
- ADAG $3.65
- MDXH $3.85
- Technical
- Relative Strength Index (RSI)
- ADAG 62.66
- MDXH 41.65
- Support Level
- ADAG $1.64
- MDXH $1.82
- Resistance Level
- ADAG $1.95
- MDXH $2.01
- Average True Range (ATR)
- ADAG 0.10
- MDXH 0.09
- MACD
- ADAG 0.04
- MDXH 0.01
- Stochastic Oscillator
- ADAG 91.30
- MDXH 46.43
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.